Risk factors

Erasca (ERAS) risk factors

Item 1A of every Erasca, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open ERAS in Gloom →
Erasca's chart, financials and news, free in your browser.Open ERAS in Gloom →
  • FY2025 10-K risk factors
    92 risks5 new5 dropped13 reworded

    Erasca added risks covering clinical trial EU regulations, foreign trial data acceptance, BIOSECURE Act restrictions, Joyo's China activities, and AI technology deployment.

    Filed Mar 12, 2026
  • FY2024 10-K risk factors
    92 risks

    Erasca focuses exclusively on the unproven RAS/MAPK pathway, relying heavily on the naporafenib clinical program and third-party manufacturers.

    Filed Mar 20, 2025